Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Red-Hot Quality Opportunities in Genomics
02:21pm, Thursday, 22'nd Jun 2023
The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive m
Natera Reexamined
12:37pm, Wednesday, 17'th May 2023
Today, we revisit genetic testing concern Natera, Inc., as the shares are up more than 30% so far in 2023. The company continues to deliver solid revenue growth even as its cash burn rate remains a co
Natera, Inc. (NTRA) Q1 2023 Earnings Call Transcript
11:07pm, Tuesday, 09'th May 2023
Natera, Inc. (NASDAQ:NTRA ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Steven Chapman - Chief Executive Officer Michael Brophy - Chief Financial Officer Alexey Aleshi
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
07:52pm, Tuesday, 09'th May 2023
Natera (NTRA) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.45 per share a year ago.
Natera Is There For A Long Game (Technical Analysis)
07:01pm, Thursday, 02'nd Mar 2023
Cutting the cash burn and other operational expenses should bring back Natera, Inc. financial health. Natera produced in 2022 loads of peer-reviewed ammunition for winning more and more market share i
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
09:50pm, Tuesday, 28'th Feb 2023
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Natera (NTRA) This Earnings Season?
09:47am, Monday, 27'th Feb 2023
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
08:00am, Tuesday, 21'st Feb 2023
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2
Why Natera Stock Is Leading Its Industry Group With A 17% Jump Today
12:51pm, Thursday, 16'th Feb 2023
Natera stock broke definitively above its 200-day line Thursday after Medicare opted to reimburse for its breast cancer test. The post Why Natera Stock Is Leading Its Industry Group With A 17% Jump To
Natera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 03'rd Jan 2023
AUSTIN, Texas--( BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 41st Annual J.P. Morgan Healthc
Natera's Worrisome Cash Burn
03:34pm, Wednesday, 14'th Dec 2022
Natera, Inc. is doubling down on its growth initiatives to expand its product portfolio beyond the non-invasive prenatal testing market. The company's growth initiatives highlight strategic discrepanc
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
08:33am, Wednesday, 07'th Dec 2022
AUSTIN, Texas , Dec. 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecula
Natera, Inc. (NTRA) Q3 2022 Earnings Call Transcript
08:13pm, Tuesday, 08'th Nov 2022
Natera, Inc. (NASDAQ:NTRA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon M
Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
07:33pm, Tuesday, 08'th Nov 2022
Natera (NTRA) delivered earnings and revenue surprises of 11.97% and 1.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Natera: Cracks In The Bearish Trade
10:32am, Monday, 10'th Oct 2022
Media reports of dramatic consequences of incorrect gene test interpretation and use combined with allegations of aggressive billing tactics drove the NTRA shares reeling. This negative publicity ali
